Notably, the anti-CD117 antibody briquilimab has shown efficacy as a conditioning agent in clinical trials involving patients with Fanconi anemia (12), MDS/AML (13), and severe combined immunodeficiency (14). The gene discussed is KIT; the disease is myelodysplastic syndrome.